Conditions: Osteoarthritis, Knee
Keywords: Primary Disease: Knee Primary Osteoarthritis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 395
Healthy volunteers: no

Brief summary:
Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

Detailed description:
Matrix metalloproteinases have been implicated in the cartilage degradation that occurs in osteoarthritis. PG-530742 inhibits some of these matrix metalloproteinases, thus potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

Arms:
arm 1: Placebo tablet arm 2: 25 mg PG-530742 arm 3: 50 mg PG-530742 arm 4: 100 mg PG-530742 arm 5: 200 mg PG-530742

Interventions: intervention 1: PG-530742 intervention 2: Placebo intervention 3: 50 mg PG-530742 intervention 4: 100 mg PG-530742 intervention 5: 200 mg PG-530742
Intervention descriptions: intervention 1: One 25 mg PG-530742 tablet, twice daily for for one year intervention 2: One placebo tablet, twice daily for for one year intervention 3: One 50 mg PG-530742 tablet, twice daily for for one year intervention 4: 100 mg PG-530742 tablet, twice a day for one year intervention 5: 200 mg PG-530742 tablet, twice a day for one year

Protocol document: